Smartinhaler maker Adherium (formerly Nexus6) has announced a new deal to provide AstraZeneca with devices and sensors for use in asthma and COPD patient support programs. AstraZeneca has already used the Adherium technology in clinical trials.
Studies have verified that Smartinhaler use significantly increases adherence to asthma medications both in children and in adults.
According to Adherium, “Initially the technology will be used to monitor patients’ use of therapy and provide personalised advice to patients based on their conditions and medication use. In the future, developments are likely to include additional sensors designed to monitor a patient’s condition and potentially to assess a patient’s personalised risk factors.”
Adherium Managing Director and CEO Garth Sutherland said, “We are very pleased to be working with AstraZeneca. These agreements represent a major advance in the treatment and management of respiratory disease, and will make a fundamental difference to the quality of life for people with asthma and COPD.”
Read the Adherium press release.
